Samsara BioCapital’s Tempest Therapeutics TPST Stock Holding History

Samsara BioCapital’s Portfolio TPST Stock Details TPST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-3,853	Closed	-$3.97M	–	35
2020 Q1	$3.97M	Buy	3,853 +185	+5%	+$270K	2.28%	12
2019 Q4	$4.82M	Buy	3,668 +2,711	+283%	+$3.82M	2.31%	12
2019 Q3	$1.33M	Buy	957 +726	+314%	+$1.17M	0.9%	17
2019 Q2	$521K	Hold	231	–	–	0.34%	18
2019 Q1	$677K	Hold	231	–	–	0.53%	15
2018 Q4	$359K	Buy	+231	New	+$475K	0.34%	14

Other funds holding TPST

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Bpifrance Maisons Alfort, Cedex, France $1.65B AUM 19.85% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Samsara BioCapital's TPST Position: Q2 2020 in Review

Samsara BioCapital sold out of Tempest Therapeutics (TPST) in Q2 2020, closing a stake of 3,853 shares — an estimated $3.97M sold.

Samsara BioCapital first reported a position in TPST in Q4 2018 and held it in 6 quarters. The position peaked at $4.82M in Q4 2019. 51 funds tracked by Wall St. Rank hold TPST as of Q2 2020.

Samsara BioCapital reported no remaining Tempest Therapeutics position as of Q2 2020 after selling out during the quarter.
Samsara BioCapital sold 3,853 Tempest Therapeutics shares in Q2 2020, an estimated $3.97M.
Samsara BioCapital first reported a position in Tempest Therapeutics in Q4 2018 and held it in 6 quarters.
Samsara BioCapital's Tempest Therapeutics position peaked at $4.82M in Q4 2019.
51 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2020.

Based on Samsara BioCapital's 13F filing for Q2 2020, filed 14 Aug 2020.